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Abstract
In 2020, the Sars-Cov-2 pandemic is causing a huge and dramatic impact on healthcare systems worldwide. During this 
emergency, fragile patients suffering from other comorbidities, especially patients susceptible to or affected by cardiovascular 
disease, are the ones most exposed to the poorer outcomes. Therefore, it is still mandatory to continue to strictly adhere to 
the rules of cardiovascular prevention. This document aims to provide all doctors with simple and clear recommendations 
in order to spread useful messages to the widest number of subjects in order to continue the battle against cardiovascular 
diseases even in times of pandemic.
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For the first time since the Second World War, the entire 
planet is facing an event, the Sars-Cov-2 pandemic, which 
is undermining our lifestyle and perception of health, as we 
are used to perceive them. The latest data show that over 
fifteen million people worldwide are affected by Covid-19 
and about 600,000 have died from it [1]. In addition, the 
burden of morbidity and mortality indirectly dependent 
on this pandemic is still not estimable, just as the conse-
quent socio-economic damage. Those who have undergone 
quarantine measures, have already experienced significant 
changes in daily life and in the management of their health 
issues, even in the fortunate case of not having contracted 
the Sars-Cov-2. On the one hand, the fear of contracting the 
infection as consequence of a simple access or admission to 
hospitals has led to a reduction in the request for medical 
treatment by patients, with heavy and in some cases fatal 
consequences. For instance, efforts to reduce social contact 
and community concerns regarding potential transmission 
have led to reduction in emergency department presenta-
tions for acute coronary syndromes including ST elevation 
myocardial infarction by more than 50% [2, 3]. On the other 
hand, due to the emergency, all health resources from the 
general practitioners’ offices to hospitals, to intensive care 
units, have been almost completely involved and devolved in 
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the management of Covid-19 patients. Hospitals have been 
hurriedly transformed creating specific wards and units and 
outpatients’ clinics have been shut down for months. Beside 
this, there are other more impalpable consequences of the 
Covid-19 pandemic that might changing our lifestyle in a 
potentially fearsome way, especially for the most fragile 
population groups. In fact, it should be remembered that 
elderly people and patients with existing comorbidities, and 
especially those of the cardiovascular (CV) system such as 
hypertension or diabetes, got sick more often for Covid-19 
and presented a very high risk of intubation and death [4–7]. 
These patients have been primary asked to stay at home and 
avoiding human contacts including those with relatives and 
doctors. These measures have obviously restricted health 
controls especially for those with chronic diseases and with 
physical restrictions.
Therefore, primary and secondary CV prevention 
efforts should not be forgotten at this time, since having 
direct implications for reducing the burden of current and 
eventual future viral outbreaks and not only to improve CV 
health [8–10]. For patients with established atherosclerotic 
CV disease (CVD), limitations in the access to the health-
care system resources has potential implications to receive 
secondary prevention strategies. This is important given 
that patients with coronary heart disease have between 
20–35% absolute risk over 5 years of experiencing a new 
heart attack, stroke or cardiovascular death with the great-
est risk occurring during the first year following hospitali-
zation for acute coronary syndrome [11]. Therefore, it is 
essential not to neglect the management of chronic dis-
eases during the pandemic. To do this it is not possible to 
simply recall the routine recommendations adopted before 
the pandemic (i.e. recommending to a hypertensive patient 
to go to the pharmacy for measuring blood pressure), but it 
is necessary to integrate the limitations imposed de facto 
by the spread of the coronavirus in the management of 
patients with chronic diseases with alternative measures, 
for instance an implemented use of telemedicine which 
can represent a valid alternative approach for several con-
ditions [12].
In this regard, there are global recommendations of gen-
eral behavior rules aimed at limiting the spread of the virus, 
that we wish to reinforce and summarize here again in view 
of their importance and of potential new waves of the dis-
ease [13]:
• Recommendation 1 To stay at home as much as possible. 
In terms of primary prevention, one approach may be 
to recommend additional isolation measures and social 
distancing for those with pre-existing CVD, similar to 
‘high-risk’ cohort such as immunosuppressed patients 
[7].
• Recommendation 2 If one experiences flu-like symptoms 
(fever, cough) or difficulty in breathing, family doctor 
needs to be contacted immediately or in more serious 
cases refer to the emergency numbers is a life-saving 
practice [13].
• Recommendation 3 To keep the safety distance with 
others, which must be at least one meter. Avoid shaking 
hands or embrace people who are not cohabitants and 
wash hands often and carefully [13].
• Recommendation 4 If one is forced to leave home, wear-
ing disposable gloves, which, on returning home, must be 
placed in a closed envelope and thrown away is a protec-
tion practice. If one has a mask, the recommendation is 
to wear it well covering nose and mouth. The wearable 
surgical mask prevents the spreading of droplets on the 
air [13].
• Recommendation 5 If one coughs or sneezes, a tissue 
should always put in front of mouth and nose and then 
must be thrown it in the toilet or in a sealed envelope 
[13].
Beside these general recommendation, and although the 
attention is focused on addressing the acute situation cre-
ated by the Covid-19 illness, it is imperative to continue our 
efforts to prevent CV morbidity and mortality, particularly 
during a period of prolonged social isolation which may 
limit physical activity and adversely affect mental health 
and psychological attitude. Indeed, the quarantine period 
allowed us to identify future battle fields for the management 
of people affected by chronic diseases, that we could list in:
• underestimation of CV symptoms by the patients,
• limitation of the chance to access to the visit in presence 
with the doctor and to drug refill,
• limitation of the chance to practice physical activity,
• limitation of access to healthy dietary advice and food.
As for the first point,
• Recommendation 6 Patients with established CVD are 
at the greatest risk of future CV events. In case of chest 
pain, dyspnea, syncope or tachycardia seeking emer-
gency medical attention remains of vital importance.
• Recommendation 7 Measure CV risk factors at home and 
stick to current treatment regimens. Promptly contact-
ing your doctor, even remotely, for any modification of 
therapy.
As for the second point, many considerations are neces-
sary. One indirect consequence of the continuing diversion 
of clinical resources required by the acute management of 
Covid-19, as mentioned above, is represented by a consider-
able reduction of routine CVD risk screening and delays in 
 follow-up appointments [14]. On the one hand, the loss of 
free access to doctors is worrying, but on the other the cur-
rent technological evolution allows us to be able to integrate 
clinical practice with telemedicine and with home control 
of risk factors [10]. Through the implementation of these 
two approaches, in fact, a constant medical relationship with 
patients can and should be preserved, in order to detect CV 
risk factors early, manage them carefully, avoiding medi-
cal inertia by doctor as well as poor adherence by patients 
[15, 16]. In fact, the control of chronic comorbidities is 
fundamental both to reduce the direct consequences of the 
virus as well as to avoid its indirect consequences given by 
the onset of CV pathologies, up to the most extreme con-
sequences. The practical consequences of treatment inertia 
have been studied in registry studies. Data from The Health 
Improvement Network (a UK primary-care database) fol-
lowed 88,756 adults with hypertension over a median fol-
low-up of 37 months after initial assessment [17]. During 
the follow-up period, 9985 (11%) participants had an acute 
CVD event or died. Retrospective analysis showed that for 
systolic blood pressure intervention thresholds, delays more 
than 1.4 months until medication intensification were associ-
ated with adverse outcomes (HR: 1.12, 95% CI 1.05–1.20; 
P < 0.009). Similarly, delays more than 2.7 months in sub-
sequent follow-up appointments were also associated with 
adverse outcomes (HR 1.18, 95% CI 1.11–1.25; P < 0.001). 
In the recent NICE hypertension guideline, immediate initia-
tion of antihypertensive medication was cost-effective com-
pared with a one-year delay for reducing CVD events in most 
individuals with stage 1 hypertension [18]. For this reason, 
we recommend the purchase of validated devices for home 
pressure monitoring, as well as the dissemination by doctors, 
through the most adequate communication channels, of the 
indications on how to measure blood pressure and what tar-
gets are to be reached, but also how to recognize concerning 
symptoms and monitor vital sings at home. Moreover, with a 
view to a general decrease in access to treatment, it has also 
been proposed to undertake anti-hypertensive therapy with 
drugs that require fewer laboratory checks and potential side 
effects such as calcium channel blockers and angiotensin 
receptors blocker/angiotensin converting enzyme inhibitors. 
Patients should also be instructed how to maintain adequate 
supplies of their chronic medication during this pandemic 
i.e. through email or home-delivery [19, 20]
At this time, telehealth can be particularly useful in 
CV medicine which heavily relies on clinical history and 
can make care more accessible and affordable potentially 
reducing disparities in access to care for rural, regional and 
remote areas [10], and for vulnerable populations (people 
with disabilities).
• Recommendation 8 Refer to reliable scientific sources 
to evaluate the impact of chronic therapies during the 
pandemic.
  It is very important not only to adhere to chronic thera-
pies which are of key importance in the prevention of CV 
disease such as anti-hypertensive therapies, lipid lower-
ing and antidiabetic drugs, but also to avoid quitting a 
therapy on the basis of unproven information or even on 
scientific reports of questionable value. Probably, never 
in the history of Medicine so many uncontrolled informa-
tion claiming that a certain drug was harmful or protec-
tive towards the virus or the course of the disease were 
delivered to the physician community or even directly 
to the public. This is for instance the case of the renin-
angiotensin blockers e.g. angiotensin receptors blocker/
angiotensin converting enzyme inhibitors, which were 
initially thought to expose more to the contagion or to 
worsen the course of the disease, then were thought to 
be protective, and finally, as shown in many articles, con-
sidered substantially neutral in Covid-19. As in all fields 
of science, these conclusions must always be supported 
by scientific proofs and patients should be encouraged to 
continue therapy which provide certain benefits vs uncer-
tain and debatable harm [21–23].
• Recommendation 9 Do about 150  min of moderate 
physical activity per week or 75 min of intense physical 
activity per week since physical activity strengthens the 
immune system and performs an anti-inflammatory and 
anti-stress action [8].
  The measures undertaken to limit the spread of coro-
navirus have also substantially changed habits regard-
ing physical activity. In fact, for a long period the sport 
centers have been locked-down and even the reopening 
presents significant limitations that do not allow a turna-
round comparable to the past. Moreover, sport centers 
remain a place perceived as potentially dangerous. Fur-
thermore, the decrease in working trips and commut-
ing, in favor of the smart working regimes, has favored 
sedentary lifestyle. A study in the USA has shown that 
physical activity, measured objectively by Fitbit trackers, 
has fallen by 39% in the month of March since social 
distancing measures were implemented [24]. This is of 
great concern, as physical activity has well-established 
benefits for primary and secondary prevention of CVD 
[25, 26]. Indeed, a sedentary life leads to an increase 
in oxidative stress with apoptotic cell death of endothe-
lial cells, reduction of nitric oxide levels, increase in 
vascular inflammation, promotion of vasoconstriction 
and LDL cholesterol oxidation [27]. Oxidative stress is 
mutually linked to inflammation, often associated with 
an increased risk of endothelial dysfunction [28]. For 
this reason, the maintenance of a healthy lifestyle must 
be encouraged, favoring activities that can be practiced 
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outdoors or at home, like treadmill or stationary cycling 
also through distance coaching, which has now become 
a viable alternative for many sports centers. Moreover, 
the use of wearable devices, such as activity trackers and 
smart watches, should be encouraged since it has dem-
onstrated potential advantages for patients to monitor 
behaviors such as physical activity and heart rate [10].
• Recommendation 10 Stick to a healthy diet by checking 
its calories. The Mediterranean Diet proves to be fun-
damental, since different foods (vegetables, fruit, extra-
virgin olive oil) are rich in vitamins and polyphenols, 
antioxidant substances that determine a lower inflamma-
tory state and a strengthening of our immune system and 
CV health [29].
  During the lockdown period the opportunities for the 
supply of necessities were reduced to a minimum. This 
indication has favored the consumption of preserved 
material, often rich in salt, added sugars and saturated 
fat, or pre-cooked meal instead of a diet rich in fresh 
food, promoting the development of CV and metabolic 
diseases. Therefore, it is recommended to stick as much 
as possible to a Mediterranean style diet, replacing the 
fresh components with the frozen ones if necessary and 
preferring the vegetable protein such as legumes over the 
preserved animal ones. indeed, a habitual legume intake 
confers a decreased risk of hypertension, type 2 diabetes, 
and hypercholesterolemia. Diets rich in fruits and vegeta-
bles have several positive effects: known health benefit 
of high flavonol intake, potential increase in nitric oxide 
species, concomitant weight loss, reduction of blood 
pressure, and reduction of inflammatory markers [30].
• Recommendation 11 Quit smoking, which is a risk factor 
for CVD and worse outcome related to Covid-19. Never 
restart smoking because of lockdown frustration.
One more crucial issue in disease prevention in Covid-
19-time, is smoking. Smoking presents a significant risk for 
patient during the Covid-19 pandemic. Indeed, smoking not 
only promotes a greater risk of future CV events, but also 
increases the risk of infection via hand-to-mouth contact, 
provides a potential adhesion site for the Sars-Cov-2 virus 
through upregulation of angiotensin-converting enzyme-2 
receptors and associates with more severe pulmonary com-
plications [10].
In summary, even though we are currently still facing a 
viral pandemic, the burden of chronic disease non-commu-
nicable diseases still put human civilization in great danger 
as CVD are the leading cause of morbidity and mortality 
worldwide [31]. Moreover, since it is now clearly docu-
mented that mortality from Covid-19 is higher in patients 
with established CVD or CV risk factors, primary and sec-
ondary CV prevention is a crucial tool to reduce the burden 
of Covid-19 related consequences on health. Even though it 
is uncertain whether the greater impact of chronic disease 
states on outcome with Covid-19 is unique to this pathogen 
or a more generalized susceptibility to illness, a healthier 
population may be more resilient to future unplanned global 
threats.
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